Piramal Pharma Solutions (PPS) maintains its position as an international leader in the development of antibody drug conjugates (ADCs) thanks to its vast technical knowledge, world-class staff, customer-centric approach, and integrated drug development and manufacturing programs. From preclinical development to sterile fill/finish, PPS can support ADC and bioconjugation process development, GMP manufacture, and scale-up to commercial. The company’s Grangemouth, Scotland facility – which boasts a legacy of over 100 years in the chemical manufacturing industry – was one of the first contract development and manufacturing organizations (CDMOs) to enter the ADC category. Over the past ~20 years, PPS has manufactured 30+ different ADC products to GMP, developed over 1000 batches for 200 different ADC candidates, and worked with over 60 different toxin/toxin linker systems. PPS was the 1st CDMO to manufacture commercial ADCs in 2011 and has been continuously manufacturing commercial ADCs since. As ADC development has grown and evolved, PPS has established new tools and unique skills to benefit its customers. The company’s flexibility, breadth of experience, and end-to-end services have secured its role as a top CDMO in this market segment. Read the whitepaper to learn more.
